J&J announces that Biosense Webster, a global specialist in the treatment of cardiac arrhythmia and part of Johnson & Johnson MedTech, has received approval from Japan's Ministry of Health, Labor and Welfare (MHLW) to market its Varipulse platform in Japan. Johnson MedTech, has received approval from Japan's Ministry of Health, Labor and Welfare (MHLW) for the Varipulse platform for the treatment of recurrent paroxysmal atrial fibrillation (PAF) by pulsed field

' At Biosense Webster, we are working to offer a differentiated range of PAF integrated with 3D cardiac mapping to meet the real and unmet needs of electrophysiologists and the patients they treat. Today, we celebrate this important milestone in the approval of the Varipulse platform, the first and only PFA system approved in Japan ', said Jasmina Brooks, President of Biosense Webster.

''We are delighted to continue advancing PFA clinical studies globally, and look forward to the positive impact this innovation will have on patients worldwide,'' she added.

Copyright (c) 2024 CercleFinance.com. All rights reserved.